JP6663428B2 - Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物 - Google Patents

Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物 Download PDF

Info

Publication number
JP6663428B2
JP6663428B2 JP2017522852A JP2017522852A JP6663428B2 JP 6663428 B2 JP6663428 B2 JP 6663428B2 JP 2017522852 A JP2017522852 A JP 2017522852A JP 2017522852 A JP2017522852 A JP 2017522852A JP 6663428 B2 JP6663428 B2 JP 6663428B2
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
acid sequence
gdf15
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017522852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533910A (ja
JP2017533910A5 (https=
Inventor
ラビンドラ クマール，
ラビンドラ クマール，
ナガ ベンカタ サイ ラジャセクハル スラガニ，
ナガ ベンカタ サイ ラジャセクハル スラガニ，
Original Assignee
アクセルロン ファーマ， インコーポレイテッド
アクセルロン ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ， インコーポレイテッド, アクセルロン ファーマ， インコーポレイテッド filed Critical アクセルロン ファーマ， インコーポレイテッド
Publication of JP2017533910A publication Critical patent/JP2017533910A/ja
Publication of JP2017533910A5 publication Critical patent/JP2017533910A5/ja
Application granted granted Critical
Publication of JP6663428B2 publication Critical patent/JP6663428B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017522852A 2014-10-30 2015-10-29 Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物 Expired - Fee Related JP6663428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072889P 2014-10-30 2014-10-30
US62/072,889 2014-10-30
PCT/US2015/058116 WO2016069925A1 (en) 2014-10-30 2015-10-29 Methods and compositions using gdf15 polypeptides for increasing red blood cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020023090A Division JP7154241B2 (ja) 2014-10-30 2020-02-14 Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物

Publications (3)

Publication Number Publication Date
JP2017533910A JP2017533910A (ja) 2017-11-16
JP2017533910A5 JP2017533910A5 (https=) 2018-12-06
JP6663428B2 true JP6663428B2 (ja) 2020-03-11

Family

ID=55858354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017522852A Expired - Fee Related JP6663428B2 (ja) 2014-10-30 2015-10-29 Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
JP2020023090A Active JP7154241B2 (ja) 2014-10-30 2020-02-14 Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020023090A Active JP7154241B2 (ja) 2014-10-30 2020-02-14 Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物

Country Status (6)

Country Link
US (2) US10603359B2 (https=)
EP (2) EP3922259B1 (https=)
JP (2) JP6663428B2 (https=)
AU (2) AU2015339134B2 (https=)
CA (1) CA2964808C (https=)
WO (1) WO2016069925A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10603359B2 (en) * 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) * 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
US12209112B2 (en) * 2022-09-15 2025-01-28 The Chinese University Of Hong Kong Methods of preventing or treating diseases, conditions, or disorders associated with chemotherapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO2000011168A2 (en) 1998-08-21 2000-03-02 Princeton University Genes that regulate hematopoietic blood forming stem cells and uses thereof
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
JP5444363B2 (ja) * 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
AU2010282361B2 (en) * 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
PH12013501969B1 (en) * 2011-03-29 2018-08-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene
EP3282257A1 (en) 2011-11-22 2018-02-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3204283A1 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2644278B1 (en) 2012-03-27 2014-12-10 Alfa Laval Corporate AB Centrifugal separator and method of controlling intermittent discharge
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (ko) * 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
JP2017509647A (ja) 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
AU2015276800B2 (en) * 2014-06-20 2021-03-04 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator
US10603359B2 (en) * 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
TWI621976B (zh) 2015-07-24 2018-04-21 瑞鼎科技股份有限公司 內嵌式觸控面板驅動方法
US20170299608A1 (en) * 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight

Also Published As

Publication number Publication date
AU2021232680A1 (en) 2021-10-07
US11642394B2 (en) 2023-05-09
AU2015339134B2 (en) 2021-06-17
JP7154241B2 (ja) 2022-10-17
JP2020073603A (ja) 2020-05-14
CA2964808C (en) 2023-06-27
JP2017533910A (ja) 2017-11-16
US20180207236A1 (en) 2018-07-26
WO2016069925A1 (en) 2016-05-06
EP3212213B1 (en) 2021-04-28
US10603359B2 (en) 2020-03-31
EP3922259B1 (en) 2026-04-01
AU2015339134A1 (en) 2017-04-27
EP3922259A1 (en) 2021-12-15
US20200397863A1 (en) 2020-12-24
EP3212213A1 (en) 2017-09-06
CA2964808A1 (en) 2016-05-06
EP3212213A4 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
JP7154241B2 (ja) Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
JP6796626B2 (ja) 無効赤血球生成を処置するための方法および組成物
JP6968917B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
JP6860533B2 (ja) 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用
JP6643432B2 (ja) アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
US10829534B2 (en) Methods and compositions for increasing red blood cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200214

R150 Certificate of patent or registration of utility model

Ref document number: 6663428

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

LAPS Cancellation because of no payment of annual fees